Incremental Consolidation in Pharmaceuticals
Executive SummaryThe drug market isn't consolidating much, despite the mergers which have taken place, according to data from PMSI International. For individual companies, the market share growth available can only practically come through acquisition, not pipeline-driven growth.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.